Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards

Osteoporosis International

Volumn 22, Issue 2, 2011, Pages 391-420

  Vasikaran, S ^a,b   Eastell, R ^c   Bruyere O ^d   Foldes, A J ^e   Garnero, P ^f   Griesmacher, A ^g   McClung, M ^h   Morris, H A ⁱ   Silverman, S ^j   Trenti, T ^k   Wahl, D A ^l   Cooper, C ^m   Kanis, J A ⁿ  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^f INSERM   (France)

^g UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^h OREGON OSTEOPOROSIS CENTER   (United States)

ⁱ UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k Nuovo Ospedale S Agostino   (Italy)

^l International Osteoporosis Foundation Switzerland   (Switzerland)

^m UNIVERSITY OF OXFORD   (United Kingdom)

ⁿ UNIVERSITY OF SHEFFIELD   (United Kingdom)

more..

Author keywords

Bone makers; Bone turnover; Fracture risk; IOF; Monitoring treatment; Reference standards

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE TURNOVER MARKER; CALCITONIN; CARBOXY TERMINAL TELOPEPTIDE; CONJUGATED ESTROGEN; DENOSUMAB; DEOXYPYRIDINOLINE; ESTRADIOL; IBANDRONIC ACID; ODANACATIB; OSTEOCALCIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHOSPHATASE; PROCOLLAGEN; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TARTARIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ASSESSMENT; CLINICAL STUDY; DRUG ACTIVITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; FRACTURE; GOLD STANDARD; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; INTERVENTION STUDY; MEDICAL PRACTICE; MEDICAL RESEARCH; MEDICAL SOCIETY; MEDLINE; OBSERVATIONAL STUDY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACODYNAMICS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; QUALITY CONTROL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY OSTEOPOROSIS; STANDARD; STANDARDIZATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; REFERENCE STANDARDS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 78651493109     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1501-1     Document Type: Article

References (157)

1. Consensus Development Conference 1993 Diagnosis, prophylaxis and treatment of osteoporosis Am J Med 94 646 650 10.1016/0002-9343(93)90218-E
2. JA Kanis O Johnell 2005 Requirements for DXA for the management of osteoporosis in Europe Osteoporos Int 16 229 238 1:STN:280: DC%2BD2M%2Fps1Shtg%3D%3D 15618996 10.1007/s00198-004-1811-2
3. R Burge B Dawson-Hughes D Solomon J Wong A King A Tosteson 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 465 475 17144789 10.1359/jbmr.061113
4. JA Kanis EV McCloskey H Johansson A Oden LJ Melton N Khaltaev 2008 A reference standard for the description of osteoporosis Bone 42 467 475 1:CAS:528:DC%2BD1cXitVOmtbk%3D 18180210 10.1016/j.bone.2007.11.001
5. JA Kanis LJ Melton C Christiansen C Johnston N Khaltaev 1994 The diagnosis of osteoporosis J Bone Miner Res 9 1137 1141 1:STN:280: DyaK2M%2FmslSisA%3D%3D 7976495 10.1002/jbmr.5650090802
6. PD Delmas 2002 Treatment of postmenopausal osteoporosis Lancet 359 2018 2026 1:CAS:528:DC%2BD38XksFKkt7g%3D 12076571 10.1016/S0140-6736(02)08827-X
7. C MacLean S Newberry M Maglione M McMahon V Ranganath M Suttorp W Mojica M Timmer A Alexander, et al. 2008 Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis Ann Intern Med 148 197 213 18087050
8. JA Kanis N Burlet C Cooper PD Delmas J-Y Reginster F Borgstrom R Rizzoli on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) 2008 European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 19 399 428 1:STN:280:DC%2BD1c3itFekuw%3D%3D 18266020 10.1007/s00198-008-0560-z
9. P Bergmann JJ Body S Boonen Y Boutsen JP Devogelaer S Goemaere JM Kaufman JY Reginster V Gangji 2009 Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club Int J Clin Pract 63 19 26 1:CAS:528:DC%2BC3cXktFGnsLc%3D 19125989 10.1111/j.1742-1241. 2008.01911.x
10. Vesper H, Cosman F, Endres DB, Garnero P, Hoyle NR, Kleerekoper M, Mallinak NJ (2004) Application of biochemical markers of bone turnover in the assessment and monitoring of bone diseases-approved guidelines. NCCLS document C48-A. ISBN 1-56238-539-9
11. JP Brown C Albert BA Nassar JD Adachi D Cole KS Davison KC Dooley A Don-Wauchope P Douville, et al. 2009 Bone turnover markers in the management of postmenopausal osteoporosis Clin Biochem 42 929 942 1:CAS:528: DC%2BD1MXnt1emt74%3D 19362543 10.1016/j.clinbiochem.2009.04.001
12. P Szulc P Delmas 2008 Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis Osteoporos Int 19 1683 1704 1:CAS:528:DC%2BD1cXht12kur7P 18629570 10.1007/s00198-008-0660-9
13. SD Vasikaran 2008 Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis Crit Rev Clin Lab Sci 45 221 258 1:CAS:528:DC%2BD1cXks12luro%3D 18415816 10.1080/10408360801949442
14. R Hannon R Eastell 2000 Preanalytical variability of biochemical markers of bone turnover Osteoporos Int 11 S30 S44 11193238 10.1007/s001980070004
15. MJ Seibel M Lang WJ Geilenkeuser 2001 Interlaboratory variation of biochemical markers of bone turnover Clin Chem 47 1443 1450 1:CAS:528: DC%2BD3MXls1SqurY%3D 11468235
16. Eisman J, Ebeling P, Ewald D, Flicker L, Holborow B, Nash P, Sambrook P, Seibel M, Stenmark J, Winzenberg T, Herjandono J (2010) Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men. The Royal Australian College of General Practitioners. www.racgp.org.au. Accessed March 2010
17. Sociedad Iberoamericana de Osteología y Metabolismo Mineral (SIBOMM) (2009) Ibero-American consensus on osteoporosis (Osteoporosis: Prevención, Diagnóstico y Tratamiento). www.aaomm.org.ar. Accessed March 2010
18. R Lorenc P Głuszko E Karczmarewicz K Ksiȩzopolska- Orłowska W Misiorowski E Franek W Horst-Sikorska M Kaleta B Mȩczekalski, et al. 2007 Recommendations on the diagnosis and treatment of osteoporosis. Reducing the incidence of fractures through effective prevention and treatment Terapia 9 11 39
19. Singapore Ministry of Health (2008) Clinical practice guidelines for osteoporosis. Ministry of Health, Singapore. www.moh.gov.sg/cpg. Accessed March 2010
20. National Osteoporosis Guideline Group (2008) Osteoporosis-clinical guideline for prevention and treatment-executive summary. www.shef.ac.uk/NOGG. Accessed March 2010
21. Dawson-Hughes B, Lindsay R, Khosla S, Melton LJ, Tosteson AN, Favus MJ, Baim S (2008) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation. www.nof.org. Accessed March 2010
22. Nelson HD, Morris CD, Kraemer DF, Mahon S, Carney N, Nygren PM, Helfand M (2001) Osteoporosis in postmenopausal women: diagnosis and monitoring. Evidence report/technology assessment no. 28. Agency for Healthcare Research and Quality, Rockville
23. R Civitelli R Armamento-Villareal N Napoli 2009 Bone turnover markers: understanding their value in clinical trials and clinical practice Osteoporos Int 20 843 851 1:STN:280:DC%2BD1MzjtVeltg%3D%3D 19190842 10.1007/s00198-009- 0838-9
24. D Leeming P Alexandersen M Karsdal P Qvist S Schaller L Tankó 2006 An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice Eur J Clin Pharmacol 62 781 792 1:STN:280:DC%2BD28rptVyitg%3D%3D 16912870 10.1007/s00228-006-0174-3
25. C Wickham K Walsh C Cooper D Barker B Margetts J Morris S Bruce 1989 Dietary calcium, physical activity, and risk of hip fracture: a prospective study Br Med J Clin Res Ed 299 889 892 1:STN:280:DyaK3c%2FlslOrtA%3D%3D 10.1136/bmj.299.6704.889
26. J Huopio H Kröger R Honkanen S Saarikoski E Alhava 2000 Risk factors for perimenopausal fractures: a prospective study Osteoporos Int 11 219 227 1:STN:280:DC%2BD3c3osVamsw%3D%3D 10824237 10.1007/s001980050284
27. MC Hochberg S Greenspan RD Wasnich P Miller DE Thompson PD Ross 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents J Clin Endocrinol Metab 87 1586 1592 1:CAS:528:DC%2BD38XivFKlt7k%3D 11932287 10.1210/jc.87.4.1586
28. AJ Darby PJ Meunier 1981 Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis Calcif Tissue Int 33 199 204 1:STN:280:DyaL38%2FgtFKguw%3D%3D 6791782 10.1007/BF02409438
29. RL Jilka 2003 Biology of the basic multicellular unit and the pathophysiology of osteoporosis Med Pediatr Oncol 41 182 185 12868116 10.1002/mpo.10334
30. P Garnero E Sornay-Rendu MC Capuy PD Delmas 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis J Bone Miner Res 11 337 349 1:CAS:528:DyaK28Xit1Cgu74%3D 8852944 10.1002/jbmr.5650110307
31. CH Chesnut NH Bell GS Clark BL Drinkwater SC English CCJ Johnson M Notelovitz C Rosen DF Cain KA Flessland NJ Mallinak 1997 Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density Am J Med 102 29 37 1:CAS:528:DyaK2sXhtlemsrw%3D 9209198 10.1016/S0002-9343(96)00387-7
32. P Peichl A Griesmacher P Pointinger R Marteau W Hartl W Gruber H Bröll 1998 Association between female sex hormones and biochemical markers of bone turnover in peri- and postmenopausal women Calcif Tissue Int 62 388 394 1:CAS:528:DyaK1cXislSksb4%3D 9541515 10.1007/s002239900450
33. C Christiansen BJ Riis P Rodbro 1987 Prediction of rapid bone loss in postmenopausal women Lancet 1 1105 1108 1:STN:280:DyaL2s3gtVCktw%3D%3D 2883442 10.1016/S0140-6736(87)91671-0
34. C Christiansen BJ Riis P Rodbro 1990 Screening procedures for women at risk of developing postmenopausal osteoporosis Osteoporos Int 1 35 40 1:STN:280:DyaK387mtlKgtA%3D%3D 2133639 10.1007/BF01880414
35. F Cosman J Nieves C Wilkinson D Schnering V Shen R Lindsay 1996 Bone density change and biochemical indices of skeletal turnover Calcif Tissue Int 58 236 243 1:CAS:528:DyaK28XitVWrt78%3D 8661954
36. PA Mole MH Walkinshaw SP Robins CR Paterson 1992 Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause? Eur J Clin Investig 22 767 771 1:STN:280:DyaK3s7it1Sltg%3D%3D 10.1111/j.1365-2362.1992.tb01444.x
37. J Reeve J Pearson A Mitchell J Green A Nicholls J Justice E Hudson L Klenerman 1995 Evolution of spinal bone loss and biochemical markers of bone remodelling after menopause in normal women Calcif Tissue Int 57 105 110 1:CAS:528:DyaK2MXnt1Ggurw%3D 7584869 10.1007/BF00298429
38. CJ Rosen CH Chesnut NJ Mallinak 1997 The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement therapy or calcium supplementation J Clin Endocrinol Metab 82 1904 1910 1:CAS:528:DyaK2sXjs1ent7Y%3D 9177404 10.1210/jc.82.6.1904
39. PD Ross W Knowlton 1998 Rapid bone loss is associated with increased levels of biochemical markers J Bone Miner Res 13 297 302 1:STN:280: DyaK1c7lsV2isA%3D%3D 9495524 10.1359/jbmr.1998.13.2.297
40. BJ Riis MA Hansen AM Jensen K Overgaard C Christiansen 1996 Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study Bone 19 9 12 1:STN:280:DyaK28vislKltw%3D%3D 8830981 10.1016/8756-3282(96)00102-0
41. J Finigan D Greenfield A Blumsohn R Hannon N Peel G Jiang R Eastell 2008 Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women J Bone Miner Res 23 75 85 17784843 10.1359/jbmr.070814
42. DW Dempster 2000 The contribution of trabecular architecture to cancellous bone quality J Bone Miner Res 15 20 23 1:STN:280: DC%2BD3c7htFGkuw%3D%3D 10646110 10.1359/jbmr.2000.15.1.20
43. H Follet G Boivin C Rumelhart PJ Meunier 2004 The degree of mineralization is a determinant of bone strength: a study on human calcanei Bone 34 783 789 1:STN:280:DC%2BD2c3it1Wksw%3D%3D 15121009 10.1016/j.bone.2003.12.012
44. X Banse TJ Sims AJ Bailey 2002 Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links J Bone Miner Res 17 1621 1628 1:CAS:528:DC%2BD38XntlSrsL8%3D 12211432 10.1359/jbmr.2002.17.9.1621
45. S Viguet-Carin JP Roux ME Arlot Z Merabet DJ Leeming I Byrjalsen PD Delmas ML Bouxsein 2006 Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae Bone 39 1073 1079 10.1016/j.bone.2006.05. 013 1:CAS:528:DC%2BD28XhtVyktrjN
46. Bauer DC (2001) Biochemical markers of bone turnover: the Study of Osteoporotic Fracture. In: Eastell R, Baumann M, Hoyle N, Wieczorek L (eds) Bone markers-biochemical and clinical perspectives. Martin Dunitz, London, pp 219-223
47. H Dobnig JC Piswanger-Solkner B Obermayer-Pietsch A Tiran A Strele E Maier P Maritschnegg G Riedmuller C Brueck A Fahrleitner-Pammer 2007 Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements J Clin Endocrinol Metab 92 1678 1686 1:CAS:528:DC%2BD2sXlt1Oktrs%3D 17311861 10.1210/jc.2006-2079
48. AM Tromp ME Ooms C Popp-Snijders JC Roos P Lips 2000 Predictors of fractures in elderly women Osteoporos Int 11 134 140 1:STN:280: DC%2BD3c3lsVensw%3D%3D 10793871 10.1007/PL00004174
49. K Akesson S Ljunghall B Jonsson I Sernbo O Johnell P Gärdsell KJ Obrant 1995 Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women J Bone Miner Res 10 1823 1829 1:STN:280:DyaK287lsFKmuw%3D%3D 8592961 10.1002/jbmr.5650101127
50. P Garnero E Hausherr M-C Chapuy C Marcelli H Grandjean C Muller C Cormier G Breart PJ Meunier PD Delmas 1996 Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study J Bone Miner Res 11 1531 1538 1:STN:280:DyaK2s%2FksVOrsQ%3D%3D 8889854 10.1002/jbmr.5650111021
51. P Gerdhem KK Ivaska SL Alatalo JM Halleen J Hellman A Isaksson K Pettersson HK Vaananen K Akesson KJ Obrant 2004 Biochemical markers of bone metabolism and prediction of fracture in elderly women J Bone Miner Res 19 386 393 1:CAS:528:DC%2BD2cXisFCrsLg%3D 15040826 10.1359/JBMR.0301244
52. PD Ross BC Kress RE Parson RD Wasnich KA Armour IA Mizrahi 2000 Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study Osteoporos Int 11 76 82 1:STN:280:DC%2BD3c7ivFKqtQ%3D%3D 10663362 10.1007/s001980050009
53. E Sornay-Rendu F Munoz P Garnero F Duboeuf PD Delmas 2005 Identification of osteopenic women at high risk of fracture: the OFELY study J Bone Miner Res 20 1813 1819 16160738 10.1359/JBMR.050609
54. PL van Daele MJ Seibel H Burger A Hofman DE Grobbee JP van Leeuwen JC Birkenhager HA Pols 1996 Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study BMJ 312 482 483 8597681
55. P Vergnaud P Garnero PJ Meunier G Breart K Kamihagi PD Delmas 1997 Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study J Clin Endocrinol Metab 82 719 724 1:CAS:528:DyaK2sXhsl2jsL4%3D 9062471 10.1210/jc.82.3.719
56. P Szulc MC Chapuy PJ Meunier PD Delmas 1993 Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women J Clin Invest 91 1769 1774 1:CAS:528:DyaK3sXktVKnsbw%3D 8473517 10.1172/JCI116387
57. RD Chapurlat P Garnero G Bréart PJ Meunier PD Delmas 2000 Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study Bone 27 283 286 1:CAS:528:DC%2BD3cXltVGqtr4%3D 10913923 10.1016/S8756-3282(00)00325-2
58. H Luukinen S-M Kakonen K Pettersson K Koski P Laippala T Lovgren S-L Kivela HK Vaananen 2000 Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin J Bone Miner Res 15 2473 2478 1:CAS:528:DC%2BD3cXovVShsL0%3D 11127212 10.1359/jbmr.2000.15.12.2473
59. P Garnero E Sornay-Rendu B Claustrat PD Delmas 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study J Bone Miner Res 15 1526 1536 1:CAS:528:DC%2BD3cXlvVSjtrg%3D 10934651 10.1359/jbmr.2000.15.8.1526
60. Greenfield DM, Hannon RA, Eastell R (2001) The association between bone turnover and fracture risk (Sheffield Osteoporosis study). In: Eastell R, Baumann M, Hoyle N, Wieczorek L (eds) Bone markers-biochemical and clinical perspectives. Martin Dunitz, London, pp 225-236
61. P Garnero P Cloos E Sornay-Rendu PER Qvist PD Delmas 2002 Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study J Bone Miner Res 17 826 833 1:CAS:528:DC%2BD38XktVSktro%3D 12009013 10.1359/jbmr.2002.17.5.826
62. O Bruyère J Collette PD Delmas A Rouillon C Roux L Seidel F Richy J-Y Reginster 2003 Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal women Maturitas 44 259 265 12697366 10.1016/S0378-5122(03)00042-2 1:CAS:528: DC%2BD3sXivFertLY%3D
63. LJ Melton III CS Crowson WM O'Fallon HW Wahner BL Riggs 2003 Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction J Bone Miner Res 18 312 318 12568408 10.1359/jbmr.2003.18.2.312
64. C Meier TV Nguyen JR Center MJ Seibel JA Eisman 2005 Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study J Bone Miner Res 20 579 587 15765176 10.1359/JBMR.041207
65. KK Ivaska P Gerdhem HK Vaananen K Akesson KJ Obrant 2010 Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years J Bone Miner Res 25 393 403 1:CAS:528:DC%2BC3cXksl2ksLs%3D 19961336 10.1359/jbmr.091006
66. DC Bauer P Garnero SL Harrison JA Cauley R Eastell KE Ensrud E Orwoll Osteoporotic Fractures in Men (MrOS) Research Group 2009 Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study J Bone Miner Res 24 2032 2038 1:CAS:528:DC%2BC3cXht1Wns78%3D 19453262 10.1359/jbmr.090526
67. O Johnell A Oden C De Laet P Garnero PD Delmas JA Kanis 2002 Biochemical indices of bone turnover and the assessment of fracture probability Osteoporos Int 13 523 526 1:STN:280:DC%2BD38zmslSntA%3D%3D 12111011 10.1007/s001980200068
68. DC Bauer PM Sklarin KL Stone DM Black MC Nevitt KE Ensrud CD Arnaud HK Genant P Garnero PD Delmas H Lawaetz SR Cummings 1999 Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures J Bone Miner Res 14 1404 1410 1:STN:280: DyaK1MzovVahsw%3D%3D 10457273 10.1359/jbmr.1999.14.8.1404
69. S Khosla LJ Melton EJ Atkinson WM O'Fallon GG Klee BL Riggs 1998 Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen J Clin Endocrinol Metab 83 2266 2274 1:CAS:528:DyaK1cXksVSjtbo%3D 9661593 10.1210/jc.83.7.2266
70. R Marcus L Holloway B Wells G Greendale MK James C Wasilauskas J Kelaghan 1999 The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial J Bone Miner Res 14 1583 1595 1:CAS:528:DyaK1MXmtVyqurs%3D 10469288 10.1359/jbmr.1999.14.9.1583
71. JJ Stepan J Pospichal J Presl V Pacovsky 1987 Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women Bone 8 279 284 1:STN:280:DyaL1c7gslWqtg%3D%3D 3501301 10.1016/8756-3282(87)90002-0
72. Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical report, Sheffield, UK. WHO Collaborating Center, University of Sheffield. Available at http://www.shef.ac.uk/FRAX/index.htm. Accessed July 2009
73. SD Berry DP Kiel MG Donaldson SR Cummings JA Kanis H Johansson EJ Samelson 2010 Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study Osteoporos Int 21 53 60 1:STN:280:DC%2BD1MfgsVChtA%3D%3D 19937426 10.1007/s00198-009-1127-3
74. J Compston A Cooper C Cooper R Francis JA Kanis D Marsh EV McCloskey DM Reid P Selby M Wilkins for the National Osteoporosis Guideline Group 2009 Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Maturitas 62 105 108 1:STN:280:DC%2BD1M3mtVehsg%3D%3D 19135323 10.1016/j.maturitas.2008.11.022
75. S Fujiwara T Nakamura H Orimo T Hosoi I Gorai A Oden H Johansson JA Kanis 2008 Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX (TM)) Osteoporos Int 19 429 435 1:STN:280: DC%2BD1c7nvF2ntw%3D%3D 18292977 10.1007/s00198-007-0544-4
76. JA Kanis D Black C Cooper P Dargent B Dawson-Hughes C De Laet PD Delmas J Eisman O Johnell on behalf of the International Osteoporosis Foundation and the National Osteoporosis Foundation, USA, et al. 2002 A new approach to the development of assessment guidelines for osteoporosis Osteoporos Int 13 527 536 1:STN:280:DC%2BD38zmslSntQ%3D%3D 12111012 10.1007/s001980200069
77. K Lippuner H Johansson JA Kanis R Rizzoli 2010 FRAX (R) assessment of osteoporotic fracture probability in Switzerland Osteoporos Int 21 381 389 1:STN:280:DC%2BC3c%2FovFCqsw%3D%3D 19517155 10.1007/s00198-009-0975-1
78. BL Riggs AM Parfitt 2005 Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling J Bone Miner Res 20 177 184 1:CAS:528:DC%2BD2MXhsFarsr8%3D 15647810 10.1359/JBMR.041114
79. M Arlot PJ Meunier G Boivin L Haddock J Tamayo R Correa-Rotter S Jasqui DW Donley GP Dalsky JS Martin EF Eriksen 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters J Bone Miner Res 20 1244 1253 1:CAS:528:DC%2BD2MXmsFyitLw%3D 15940379 10.1359/JBMR.050309
80. M McClung E Lewiecki S Cohen M Bolognese G Woodson A Moffett M Peacock P Miller S Lederman, et al. 2006 Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 821 831 1:CAS:528:DC%2BD28Xhsl2gs7o%3D 16495394 10.1056/NEJMoa044459
81. SD Vasikaran S Khan EV McCloskey JA Kanis 1995 Sustained response to intravenous alendronate in postmenopausal osteoporosis Bone Miner 17 517 520 1:CAS:528:DyaK28XlvF2jtg%3D%3D
82. K Saag R Lindsay A Kriegman E Beamer W Zhou 2007 A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density Bone 40 1238 1243 1:CAS:528:DC%2BD2sXktF2nsrg%3D 17347063 10.1016/j.bone.2007.01.016
83. CH Chesnut S Silverman K Andriano H Genant A Gimona S Harris D Kiel M LeBoff M Maricic, et al. 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study Am J Med 109 267 276 1:CAS:528:DC%2BD3cXms1Wku70%3D 10996576 10.1016/S0002-9343(00)00490-3
84. PJ Meunier C Roux E Seeman S Ortolani JE Badurski TD Spector J Cannata A Balogh E-M Lemmel, et al. 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 468 1:CAS:528:DC%2BD2cXos1Snsw%3D%3D 14749454 10.1056/NEJMoa022436
85. O Bruyère J Collette R Rizzoli C Decock S Ortolani C Cormier J Detilleux J-Y Reginster 2010 Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years Osteoporos Int 21 1031 1036 19813043 10.1007/s00198-009-1078-8 1:CAS:528:DC%2BC3cXlsFaitLg%3D
86. K Naylor J Clowes J Finigan M Paggiosi N Peel R Eastell 2010 The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women Bone 46 592 597 1:CAS:528:DC%2BC3cXitV2htbo%3D 19897063 10.1016/j.bone.2009.10. 043
87. B Ettinger DM Black BH Mitlak RK Knickerbocker T Nickelsen HK Genant C Christiansen PD Delmas JR Zanchetta, et al. 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA 282 637 645 1:CAS:528: DyaK1MXlvVKqurg%3D 10517716 10.1001/jama.282.7.637
88. K Prestwood M Gunness D Muchmore Y Lu M Wong L Raisz 2000 A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women J Clin Endocrinol Metab 85 2197 2202 1:CAS:528:DC%2BD3cXlsVequ7g%3D 10852452 10.1210/jc.85.6.2197
89. C Pereda R Hannon K Naylor R Eastell 2002 The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women Br J Obstet Gynaecol 109 812 820 1:CAS:528:DC%2BD38Xltlertb8%3D 10.1111/j.1471-0528.2002.01177.x
90. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut Iii J Brown EF Eriksen, et al. 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial JAMA 282 1344 1352 1:CAS:528:DyaK1MXmvFansr0%3D 10527181 10.1001/jama.282.14.1344
91. C Rosen M Hochberg S Bonnick M McClung P Miller S Broy R Kagan E Chen R Petruschke D Thompson A de Papp 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study J Bone Miner Res 20 141 151 1:CAS:528:DC%2BD2MXptValtA%3D%3D 15619680 10.1359/JBMR.040920
92. R Hannon J Clowes A Eagleton H Al R Eastell A Blumsohn 2004 Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption Bone 34 187 194 1:CAS:528:DC%2BD2cXnvVCguw%3D%3D 14751577 10.1016/j.bone.2003.04.002
93. R Emkey P Delmas M Bolognese J Borges F Cosman S Ragi-Eis C Recknor C Zerbini C Neate F Sedarati S Epstein 2009 Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study Clin Ther 31 751 761 1:CAS:528:DC%2BD1MXmsFelsLo%3D 19446148 10.1016/j.clinthera.2009.04.018
94. PD Delmas RR Recker CH Chesnut A Skag JA Stakkestad R Emkey J Gilbride RC Schimmer C Christiansen 2004 Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study Osteoporos Int 15 792 798 1:CAS:528: DC%2BD2cXnsVCit7g%3D 15071723 10.1007/s00198-004-1602-9
95. P Delmas S Adami C Strugala J Stakkestad J Reginster D Felsenberg C Christiansen R Civitelli M Drezner, et al. 2006 Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study Arthritis Rheum 54 1838 1846 1:CAS:528:DC%2BD28Xms1Sjurs%3D 16729277 10.1002/art.21918
96. P Miller M McClung L Macovei J Stakkestad M Luckey B Bonvoisin J Reginster R Recker C Hughes, et al. 2005 Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res 20 1315 1322 1:CAS:528:DC%2BD2MXovV2msrk%3D 16007327 10.1359/JBMR.050313
97. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 1:CAS:528: DC%2BD2sXltVSktLc%3D 17476007 10.1056/NEJMoa067312
98. SR Cummings MJ San MR McClung ES Siris R Eastell IR Reid PD Delmas HB Zoog M Austin, et al. 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756 765 1:CAS:528:DC%2BD1MXhtVWls7nF 19671655 10.1056/NEJMoa0809493
99. HG Bone MA Bolognese CK Yuen DL Kendler H Wang Y Liu J San Martin 2008 Effects of denosumab on bone mineral density and bone turnover in postmenopausal women J Clin Endocrinol Metab 93 2149 2157 1:CAS:528:DC%2BD1cXntFamtrg%3D 18381571 10.1210/jc.2007-2814
100. E Lewiecki P Miller M McClung S Cohen M Bolognese Y Liu A Wang S Siddhanti L Fitzpatrick 2007 Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD J Bone Miner Res 22 1832 1841 1:CAS:528:DC%2BD2sXhsVyjtrjF 17708711 10.1359/jbmr.070809
101. S Glover R Eastell E McCloskey A Rogers P Garnero J Lowery R Belleli T Wright M John 2009 Rapid and robust response of biochemical markers of bone formation to teriparatide therapy Bone Miner 45 1053 1058 1:CAS:528: DC%2BD1MXhtlGit7bL
102. S Greenspan H Bone M Ettinger D Hanley R Lindsay J Zanchetta C Blosch A Mathisen S Morris T Marriott 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial Ann Intern Med 146 326 339 17339618
103. D Black M Bouxsein L Palermo J McGowan D Newitt E Rosen S Majumdar C Rosen 2008 Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling J Clin Endocrinol Metab 93 2166 2172 1:CAS:528:DC%2BD1cXntFamtrY%3D 18349061 10.1210/jc.2007-2781
104. D Black J Bilezikian K Ensrud S Greenspan L Palermo T Hue T Lang J McGowan C Rosen 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis N Engl J Med 353 555 565 1:CAS:528: DC%2BD2MXnsVWmtb0%3D 16093464 10.1056/NEJMoa050336
105. G Blake J Compston I Fogelman 2009 Could strontium ranelate have a synergistic role in the treatment of osteoporosis? J Bone Miner Res 24 1354 1357 1:CAS:528:DC%2BD1MXhtFaitrvE 19558313 10.1359/jbmr.090601
106. H Bone M McClung C Roux R Recker J Eisman N Verbruggen C Hustad C DaSilva A Santora B Ince 2010 Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density J Bone Miner Res 25 937 947 19874198
107. P Garnero W Shih E Gineyts D Karpf P Delmas 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment J Clin Endocrinol Metab 79 1693 1700 1:CAS:528:DyaK2MXislWiuro%3D 7989477 10.1210/jc.79.6.1693
108. SJ Glover M Gall O Schoenborn-Kellenberger M Wagener P Garnero S Boonen JA Cauley DM Black PD Delmas R Eastell 2009 Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States J Bone Miner Res 24 389 397 18665786 10.1359/jbmr.080703
109. SJ Glover P Gamero K Naylor A Rogers R Eastell 2008 Establishing a reference range for bone turnover markers in young, healthy women Bone 42 623 630 1:CAS:528:DC%2BD1cXjs1Whur0%3D 18289953 10.1016/j.bone.2007.12.218
110. AE de Papp HG Bone MP Caulfield R Kagan A Buinewicz E Chen E Rosenberg RE Reitz 2007 A cross-sectional study of bone turnover markers in healthy premenopausal women Bone 40 1222 1230 17331821 10.1016/j.bone.2007.01.008
111. S Adami G Bianchi ML Brandi S Giannini S Ortolani O DiMunno B Frediani M Rossini on behalf of the BONTURNO study group 2008 Determinants of bone turnover markers in healthy premenopausal women Calcif Tissue Int 82 341 347 1:CAS:528:DC%2BD1cXnsVCmsbg%3D 18470550 10.1007/s00223-008-9126-5
112. P Garnero O Borel PD Delmas 2001 Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis Clin Chem Lab Med 47 694 702 1:CAS:528:DC%2BD3MXis1Kju70%3D
113. P Garnero P Vergnaud N Hoyle 2008 Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis Clin Chem 54 188 196 1:CAS:528:DC%2BD1cXmtFersg%3D%3D 17998267 10.1373/clinchem.2007.094953
114. A Rogers SJ Glover R Eastell 2009 A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover
115. R Hannon A Blumsohn K Naylor R Eastell 1998 Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability J Bone Miner Res 13 1124 1133 1:CAS:528:DyaK1cXks1arsr0%3D 9661076 10.1359/jbmr.1998.13.7.1124
116. R Eastell JH Krege P Chen EV Glass J-Y Reginster 2006 Development of an algorithm for using PINP to monitor treatment of patients with teriparatide Curr Med Res Opin 22 61 66 1:CAS:528:DC%2BD28XhsFGqtbo%3D 16393431 10.1185/030079905X75096
117. S Greenspan N Resnick R Parker 2005 Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial J Clin Endocrinol Metab 90 2762 2767 1:CAS:528:DC%2BD2MXkt1Wgtr0%3D 15713726 10.1210/jc.2004-1091
118. P Chen JH Satterwhite AA Licata EM Lewiecki AA Sipos DM Misurski RB Wagman 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis J Bone Miner Res 20 962 970 1:CAS:528:DC%2BD2MXlsFehtr0%3D 15883636 10.1359/JBMR.050105
119. SR Cummings DB Karpf F Harris HK Genant K Ensrud AZ LaCroix DM Black 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 281 289 1:CAS:528:DC%2BD38XhvVWkurk%3D 11893367 10.1016/S0002-9343(01)01124-X
120. NB Watts C Cooper R Lindsay R Eastell MD Manhart IP Barton TP van Staa JD Adachi 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk J Clin Densitom 7 255 261 15319494 10.1385/JCD:7:3:255
121. S Sarkar BH Mitlak M Wong JL Stock DM Black KD Harper 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy J Bone Miner Res 17 1 10 1:CAS:528:DC%2BD38XktFyisg%3D%3D 11771654 10.1359/jbmr.2002.17.1.1
122. PD Delmas E Seeman 2004 Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy Bone 34 599 604 1:CAS:528:DC%2BD2cXisF2ntL4%3D 15050889 10.1016/j.bone.2003.12.022
123. R Eastell I Barton RA Hannon A Chines P Garnero PD Delmas 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 1051 1056 1:CAS:528: DC%2BD3sXkslOhsb0%3D 12817758 10.1359/jbmr.2003.18.6.1051
124. J-Y Reginster S Sarkar B Zegels Y Henrotin O Bruyere D Agnusdei J Collette 2004 Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk Bone 34 344 351 1:CAS:528:DC%2BD2cXhtFWms74%3D 14962813 10.1016/j.bone.2003.10.004
125. S Sarkar J-Y Reginster GG Crans A Diez-Perez KV Pinette PD Delmas 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk J Bone Miner Res 19 394 401 15040827 10.1359/JBMR.0301243
126. DC Bauer DM Black P Garnero M Hochberg S Ott J Orloff DE Thompson SK Ewing PD Delmas 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial J Bone Miner Res 19 1250 1258 15231011 10.1359/JBMR.040512
127. PD Delmas F Munoz DM Black F Cosman S Boonen NB Watts D Kendler EF Eriksen PG Mesenbrink R Eastell The HORIZON-PFT Research Group 2009 Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis J Bone Miner Res 24 1544 1551 1:CAS:528:DC%2BD1MXht1Wju7%2FI 19338427 10.1359/jbmr.090310
128. NH Bjarnason S Sarkar T Duong B Mitlak PD Delmas C Christiansen 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis Osteoporos Int 12 922 930 1:CAS:528:DC%2BD38XkslSkug%3D%3D 11808544 10.1007/s001980170020
129. Z Li MP Meredith MS Hoseyni 2002 A method to assess the proportion of treatment effect explained by a surrogate endpoint Stat Med 20 7531 7588
130. LS Freedman BI Graubard A Schatzkin 1992 Statistical validation of intermediate endpoints for chronic diseases Stat Med 11 167 178 1:STN:280:DyaK383ltlyrtQ%3D%3D 1579756 10.1002/sim.4780110204
131. R Eastell RA Hannon P Garnero MJ Campbell PD Delmas 2007 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis J Bone Miner Res 22 1656 1660 17931100 10.1359/jbmr.07090b
132. DC Bauer P Garnero MC Hochberg A Santora P Delmas SK Ewing DM Black 2006 Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial J Bone Miner Res 21 292 299 1:CAS:528:DC%2BD28Xhs1Kmu7Y%3D 16418785 10.1359/JBMR.051018
133. SW Veitch SC Findlay AJ Hamer A Blumsohn R Eastell BM Ingle 2006 Changes in bone mass and bone turnover following tibial shaft fracture Osteoporos Int 17 364 372 1:STN:280:DC%2BD287msF2gtg%3D%3D 16362144 10.1007/s00198-005-2025-y
134. M Hansen K Overgaard B Riis C Christiansen 1991 Potential risk factors for development of postmenopausal osteoporosis-examined over a 12-year period Osteoporos Int 1 95 102 1:STN:280:DyaK387mtlKmsg%3D%3D 1790399 10.1007/BF01880450
135. PD Delmas R Eastell P Garnero MJ Seibel J Stepan 2000 The use of biochemical markers of bone turnover in osteoporosis Osteoporos Int 11 S2 S17 11193237 10.1007/s001980070002
136. FE McKiernan RL Berg JG Linneman 2010 The utility of BMD Z-score diagnostic thresholds for secondary causes of osteoporosis Osteoporos Int 10.1007/s00198-00010-01307-00191
137. MJ Seibel V Naganathan I Barton A Grauer 2004 Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate J Bone Miner Res 19 323 329 1:CAS:528:DC%2BD2cXhs1elsrs%3D 14969403 10.1359/JBMR.0301231
138. P Delmas A Licata J Reginster G Crans P Chen D Misurski R Wagman B Mitlak 2006 Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover Bone Miner 39 237 243 1:CAS:528: DC%2BD28Xls1ejt70%3D
139. J Collette O Bruyère J Kaufman R Lorenc D Felsenberg T Spector M Diaz-Curiel S Boonen J Reginster 2010 Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover Osteoporos Int 21 233 241 1:CAS:528:DC%2BC3cXjtl2nsQ%3D%3D 19436941 10.1007/s00198-009-0940-z
140. J Blouin A Dragomir LG Ste-Marie JC Fernandes S Perreault 2007 Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women J Clin Endocrinol Metab 92 887 894 1:CAS:528:DC%2BD2sXjtlGnurc%3D 17200172 10.1210/jc.2006-1856
141. J Blouin A Dragomir Y Moride LG Ste-Marie JC Fernandes S Perreault 2008 Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women Br J Clin Pharmacol 66 117 127 1:CAS:528:DC%2BD1cXptVKis7c%3D 18460036 10.1111/j.1365-2125.2008.03178.x
142. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen TA Abbott S Silverman 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from two US claims databases Mayo Clin Proc 81 1013 1022 16901023 10.4065/81.8.1013
143. JA Clowes NF Peel R Eastell 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial J Clin Endocrinol Metab 89 1117 1123 1:CAS:528:DC%2BD2cXisVWrtbo%3D 15001596 10.1210/jc.2003-030501
144. PD Delmas B Vrijens R Eastell C Roux HA Pols JD Ringe A Grauer D Cahall NB Watts Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 92 1296 1304 1:CAS:528:DC%2BD2sXksVSrsbc%3D 17244788 10.1210/jc.2006-1526
145. N Foged J Delaissé P Hou H Lou T Sato B Winding M Bonde 1996 Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay J Bone Miner Res 11 226 237 1:CAS:528:DyaK28XhsF2ksb0%3D 8822347 10.1002/jbmr.5650110212
146. M Panteghini 2007 Traceability, reference systems and result comparability Clin Biochem Rev 28 97 104 17909614
147. MM Müller 2000 Implementation of reference systems in laboratory medicine Clin Chem 46 1907 1909 11106321
148. W Hoelzel C Weykamp JO Jeppsson K Miedema JR Barr I Goodall T Hoshino GW John U Kobold on behalf of the IFCC Working Group on HbA1c Standardization, et al. 2004 IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study Clin Chem 50 166 174 1:CAS:528: DC%2BD2cXovFWnsg%3D%3D 14709644 10.1373/clinchem.2003.024802
149. M Panteghini D Bunk R Christenson A Katrukha R Porter H Schimmel L Wang J Tate The IFCC Working Group on Standardization of Troponin I 2008 Standardization of troponin I measurements: an update Clin Chem Lab Med 46 1501 1506 1:CAS:528:DC%2BD1cXhsVOjtL%2FF 18778218 10.1515/CCLM.2008.291
150. TA Stamey Z Chen AF Prestigiacomo 1998 Reference material for PSA: the IFCC standardization study Clin Biochem 31 473 481 10.1016/S0009-9120(98)00055-1
151. U Stenman 2004 Standardization of assays for human chorionic gonadotropin Clin Chem 50 798 800 1:CAS:528:DC%2BD2cXjvVaktrk%3D 15105346 10.1373/clinchem.2003.031013
152. LM Thienpont K van Uytfanghe G Beastall JD Faix T Ieiri WG Miller JC Nelson C Ronin HA Ross JH Thijssen B Toussaint for the IFCC Working Group on Standardization of Thyroid Function Tests 2010 Report of the IFCC Working Group for Standardization of Thyroid Function Tests; part 1: thyroid-stimulating hormone Clin Chem 56 902 911 1:CAS:528:DC%2BC3cXnt1Krsr0%3D 20395624 10.1373/clinchem.2009.140178
153. LM Thienpont K van Uytfanghe AP De Leenheer 2002 Reference measurement systems in clinical chemistry Clin Chim Acta 323 73 87 1:CAS:528: DC%2BD38Xls1agtbg%3D 12135808 10.1016/S0009-8981(02)00188-2
154. HA Morris 2009 Traceability and standardization of immunoassays: a major challenge Clin Biochem 42 241 245 1:STN:280:DC%2BD1Mjit1GnsA%3D%3D 19863913 10.1016/j.clinbiochem.2008.09.005
155. M Panteghini 2009 Traceability as a unique tool to improve standardization in laboratory medicine Clin Biochem 42 236 240 19863912 10.1016/j.clinbiochem.2008.09.098
156. RH Christenson SH Duh FS Apple GS Bodor DM Bunk M Panteghini MJ Welch AHB Wu SE Kahn for the American Association for Clinical Chemistry Cardiac Troponin I Standardization Committee 2006 Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays Clin Chem 52 1685 1692 1:CAS:528:DC%2BD28Xpt1Witrw%3D 16858078 10.1373/clinchem.2006.068437
157. GG Klee 2010 Harmonization and standardization of thyroid function tests Clin Chem 56 879 880 1:CAS:528:DC%2BC3cXnt1Kku7k%3D 20378766 10.1373/clinchem.2010.145540